Gale E Smith

US Patent:

7598075, Oct 6, 2009

Filed:

Apr 1, 2005

Appl. No.:

11/097994

Inventors:

Gale E. Smith - Darnestown MD, US
John Knell - Rockville MD, US
Andrei I. Voznesensky - West Hartford CT, US

Assignee:

Protein Sciences Corporation - Meriden CT

International Classification:

C12M 1/12

US Classification:

4352972

Abstract:

Disclosed and claimed is apparatus and methods for the growth of cells to high density, products therefrom and uses thereof. Also disclosed and claimed is the use of this method for the growth to high-density insect cells, such as the Sf900+ cell line (ATCC: CRL 12579). Further disclosed is the infection of Sf900+ cells at high cell density with wild type and recombinant baculoviruses to produce baculovirus and DNA or gene or expression products.

US Patent:

7879601, Feb 1, 2011

Filed:

Oct 5, 2009

Appl. No.:

12/573468

Inventors:

Gale E. Smith - Darnestown MD, US
John Knell - Rockville MD, US
Andrei I. Voznesensky - West Hartford CT, US

Assignee:

Protein Sciences Corporation - Meriden CT

International Classification:

C12M 1/12

US Classification:

4352972

Abstract:

Disclosed and claimed is apparatus and methods for the growth of cells to high density, products therefrom and uses thereof. Also disclosed and claimed is the use of this method for the growth to high-density insect cells, such as the Sf900+ cell line (ATCC: CRL 12579). Further disclosed is the infection of Sf900+ cells at high cell density with wild type and recombinant baculoviruses to produce baculovirus and DNA or gene or expression products.

US Patent:

8026096, Sep 27, 2011

Filed:

Jan 18, 2000

Appl. No.:

09/484886

Inventors:

Gale E. Smith - Wallingford CT, US
John Knell - Meriden CT, US
Andrei I. Voznesensky - West Hartford CT, US

Assignee:

Protein Sciences Corporation - Meriden CT

International Classification:

C12N 5/00
C12N 15/00
C08H 1/00
A23J 3/12
C07K 1/00
C07K 14/00
C07K 16/00
C07K 17/00

US Classification:

435348, 435384, 435387, 4353201, 530350, 530395, 530402, 530412, 530416

Abstract:

Disclosed and claimed is a human erythropoietin (EPO) expressed and produced in Sf900+ cell line (ATCC: CRL 12579) transfected with a baculovirus construct containing the EPO gene. The EPO has an in vivo activity of 200,000 U/mg to 500,000 U/mg.

US Patent:

8080255, Dec 20, 2011

Filed:

Oct 18, 2006

Appl. No.:

11/582540

Inventors:

Gale Smith - Rockville MD, US
Rick Bright - Rockville MD, US
Peter Pushko - Rockville MD, US
Jinyou Zhang - Rockville MD, US
Kutub Mahmood - Rockville MD, US

Assignee:

Novavax Inc. - Rockville MD

International Classification:

A61K 39/145

US Classification:

4242101, 4242091, 4242051, 4242061

Abstract:

The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

US Patent:

8506967, Aug 13, 2013

Filed:

Dec 19, 2008

Appl. No.:

12/340186

Inventors:

Gale Smith - Rockville MD, US
Rick Bright - Washington DC, US
Peter M. Pushko - Rockville MD, US
Jinyou Zhang - Plainsboro NJ, US
Kutub Mahmood - Cupertino CA, US

Assignee:

Novavax, Inc. - Rockville MD

International Classification:

A61K 39/145

US Classification:

4242101, 4242091, 4242061, 4242051

Abstract:

The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

US Patent:

8551756, Oct 8, 2013

Filed:

Jan 19, 2010

Appl. No.:

12/689826

Inventors:

Gale Smith - Rockville MD, US
Peter Pushko - Frederick MD, US

Assignee:

Novavax, Inc. - Rockville MD

International Classification:

C12N 7/00
C12N 7/04

US Classification:

4352351, 435 691, 435236, 435239

Abstract:

This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

US Patent:

20020071848, Jun 13, 2002

Filed:

Jan 22, 1999

Appl. No.:

09/235901

Inventors:

GALE EUGENE SMITH - WALLINGFORD CT, US
BETHANIE E. WILKINSON - HIGGANUM CT, US
ANDREI I. VOZNESENSKY - WEST HARTFORD CT, US
FRANKLIN VOLVOVITZ - WOODBRIDGE CT, US
CRAIG S. HACKETT - WALLINGFORD CT, US

International Classification:

A61K039/12
A61K039/00
A01N037/18

US Classification:

424/204100, 424/184100, 514/002000

Abstract:

Improved mammalian virus vaccines are combinations that contain an immunogenic amount of inactivated virus, such as influenza virus, Herpes varicella virus, measles virus, Epstein Barr virus, respiratory syncytial virus, parainfluenza 3, Herpes simplex type 1 virus, and Herpes simplex type 2 virus, and an immunogenic amount of a purified recombinant envelope protein from the virus, or a fragment or precursor of the protein. Alternatively, they contain either inactivated virus and/or envelope protein antigens and an adjuvant such as granulocyte-microphage colony stimulating factor. One embodiment of an influenza vaccine is prepared by combining inactivated virus, preferably three strains of the virus, and hemagglutinin, preferably a combination of respective hemagglutinins for each of the three strains present. In another embodiment, an influenza vaccine is prepared by combining inactivated virus, again preferably three strains of the virus, and neuraminidase, preferably a combination of respective neuraminidase for each of the three strains present. In a third embodiment, the vaccine contains inactivated virus and both hemagglutinin and neuraminidase, preferably using three strains of each. Granulocyte-macrophage colony stimulating factor is, optionally, added to these embodiments.

US Patent:

20030165521, Sep 4, 2003

Filed:

Oct 4, 2002

Appl. No.:

10/264813

Inventors:

Gale Smith - Wallingford CT, US
James Matthews - Allamuchy NJ, US
Edwin Kilbourne - Madison CT, US
Bert Johansson - Armonk NY, US
Bethanie Wilkinson - Higganum CT, US
Andrei Voznesensky - West Hartford CT, US
Craig Hackett - Wallingford CT, US
Franklin Volvovitz - Woodbridge CT, US

International Classification:

A61K039/12
A61K039/21

US Classification:

424/186100, 424/208100

Abstract:

An anti-influenza vaccine composition wherein the improvement is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The composition can include and be administered with an adjuvant. The vaccine composition provides protection in a host, animal or human, against influenza infection, including viral replication and systemic infection. Oral, nasal or other mucosal or per needle administration, including intracutaneous, intradermal, intermuscular, intravascular, and intravenous injections, are included.